Author

Gregory L. Szeto

h-index 3 View on Semantic Scholar

We have 3 of 8 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Deconvolution of the mechanisms of T cell drug response in multiple myeloma induction therapy

Lenalidomide (Revlimid™), bortezomib (Velcade™), and dexamethasone, are used alone or in combination (RVd therapy) as first-line therapies for hematologic malignancies including the plasma cell dyscrasia, Multiple Myeloma (MM). The effects of RVd treatment on tumor cells have been documented, but little is known about...

Lucas T. Graybuck, L. Okada, Wei-Ling Chang et al. · bioRxiv · 0 citations

Open access Sep 2026

Enfortumab vedotin induces immunogenic cell death and shows enhanced preclinical antitumor activity when combined with a PD-1 inhibitor

Vaccination with enfortumab vedotin-treated tumor cells results in protection against tumor rechallenge in mice, consistent with antitumor immunity, and MMAE-mediated ICD induction modulates the tumor microenvironment in a complementary manner to immune checkpoint inhibition.

Devra J. Olson, Bernard A. Liu, Patrick Younan et al. · Cell Reports Medicine · 0 citations

Open access Sep 2026

20 PF-08634404 (SSGJ-707), a Tetravalent PD-1/VEGF Bispecific Antibody for the Treatment of Renal Cell Carcinoma (NCT07227415)

Abstract Background Renal cell carcinoma (RCC) is characterized by an immunogenic tumor microenvironment and frequent activation of angiogenic pathways. Therefore, combining immune checkpoint blockade with VEGF pathway inhibition is a rational therapeutic approach. PF‑08634404 is an investigational anti–PD‑1 and anti‑V...

T. Choueiri, S. Pal, T. Powles et al. · The Oncologist · 0 citations